Literature DB >> 17608817

Psychosocial impairment in patients treated for pituitary disease: a controlled study.

Nicoletta Sonino1, Chiara Ruini, Cecilia Navarrini, Fedra Ottolini, Laura Sirri, Agostino Paoletta, Francesco Fallo, Marco Boscaro, Giovanni A Fava.   

Abstract

OBJECTIVE: To verify whether patients with pituitary disorders in remission and on appropriate treatment display significant differences in psychological distress compared to healthy controls and other patients treated for nonpituitary endocrine disorders.
DESIGN: A single-centred, controlled study. PATIENTS: Eighty-six outpatients cured or in remission for at least 9 months following appropriate treatment by surgery, irradiation and/or pharmacological interventions for pituitary disease were compared with 86 healthy subjects. A sample comprising 60 outpatients cured or in remission from nonpituitary endocrine disorders was also compared. MEASUREMENTS: (1) A modified version of the Structural Clinical Interview for DSM-IV; (2) a shortened version of the structured interview for the Diagnostic Criteria for Psychosomatic Research (DCPR); (3) the Psychosocial Index (PSI); and (4) the Medical Outcomes Study (MOS) short form General Health Survey (SF-20) were employed.
RESULTS: Patients with pituitary disease displayed a higher prevalence of psychiatric disease (P < 0.001) compared to controls, but not when compared to nonpituitary endocrine patients. They also showed a higher prevalence of DCPR clusters compared to controls (P < 0.001), but not when compared to nonpituitary endocrine patients. At PSI and MOS (SF-20), patients with endocrine disease, whether pituitary or not, reported more psychological distress, and less well-being (P < 0.001) compared to controls.
CONCLUSIONS: At follow-up after appropriate treatment, we documented a high prevalence of psychopathology in patients with pituitary disease, which was however, similar to that found in nonpituitary endocrine patients. This is consistent with an increasing body of literature that reports difficulties in obtaining full recovery in patients treated for endocrine disorders.

Entities:  

Mesh:

Year:  2007        PMID: 17608817     DOI: 10.1111/j.1365-2265.2007.02951.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

Review 1.  Criteria for psychosomatic research (DCPR) in the medical setting.

Authors:  Piero Porcelli; Chiara Rafanelli
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

2.  Impaired decision making and delayed memory are related with anxiety and depressive symptoms in acromegaly.

Authors:  Iris Crespo; Alicia Santos; Elena Valassi; Patricia Pires; Susan M Webb; Eugenia Resmini
Journal:  Endocrine       Date:  2015-05-28       Impact factor: 3.633

Review 3.  Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies.

Authors:  Cornelie D Andela; Margreet Scharloo; Alberto M Pereira; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

Review 4.  Psychological well-being revisited: advances in the science and practice of eudaimonia.

Authors:  Carol D Ryff
Journal:  Psychother Psychosom       Date:  2013-11-19       Impact factor: 17.659

5.  Quality of life in female patients with acromegaly.

Authors:  O Celik; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2012-11-26       Impact factor: 4.256

6.  The psychological burden of an initially unexplained illness: patients with sternocostoclavicular hyperostosis before and after delayed diagnosis.

Authors:  Willem A van der Kloot; Neveen A T Hamdy; Laurian C S Hafkemeijer; Femke M C den Dulk; Sadhna A Chotkan; Arnold A P van Emmerik; Ad A Kaptein
Journal:  Health Qual Life Outcomes       Date:  2010-09-09       Impact factor: 3.186

7.  Pituitary Macroadenoma Presenting with Multiple Psychiatric Complications.

Authors:  Mamta Sood; Bichitra Nanda Patra; Alok Agrawal; Sudhir K Khandelwal
Journal:  Indian J Psychol Med       Date:  2015 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.